Procot

Quick links to important sections

Procot

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Procot

What is Procot? An Overview

The medicine Procot provides relief by acting on the central nervous system. Its identity, class, and general purpose are defined by its core chemical component, prochlorperazine.

Property Description
Active ingredient Prochlorperazine (INN)
Pharmacological class Phenothiazine derivative, First-generation Antipsychotic
Common use Anti-emetic (anti-sickness) agent
Origin Synthetic chemical compound
Typical Forms Oral tablet, Rectal suppository, Parenteral solution

Defining Procot: Classification and Chemical Composition

Procot is a synthetic, single-ingredient pharmaceutical preparation containing the active substance prochlorperazine (INN). The medication is chemically classified as a phenothiazine derivative and belongs to the drug category known as first-generation (typical) antipsychotic agents. The drug is characterized by this classification and its primary anti-emetic action. This medicine's chemical framework is recognized for its ability to block signals that cause feelings of nausea and the urge to vomit. Procot is a prescription-only medication, distinguishing it from over-the-counter anti-sickness aids.


Procot's Forms and Administration Types

Procot is produced in several distinct dosage forms to accommodate various patient needs. These preparations typically include solid oral tablets for ingestion, specialized rectal suppositories that serve as a crucial alternative when the oral route is compromised (such as during active vomiting), and a sterile parenteral solution suitable for administration via injection (intramuscular or intravenous). The availability of both oral and non-oral forms highlights Procot's positioning for managing acute, severe episodes where prompt, reliable delivery of the active agent is required.


General Action and Core Therapeutic Purpose

The fundamental action of Procot is rooted in its role as a potent dopamine receptor antagonist. The drug primarily works by blocking these receptors in the brain's specialized area, the chemoreceptor trigger zone (CTZ). This central mechanism is the foundation for the drug’s core therapeutic purpose: to function as an effective antiemetic agent that provides relief from intense nausea and prevents vomiting. Its pharmacological class also makes it suitable for managing severe agitation and disturbed mental states. The medication is utilized in scenarios requiring management of severe motion sickness or vestibular conditions, reflecting its central depressant effect.

What side effects are possible with Procot?

Possible Side Effects and Safety Information

The officially documented adverse effects of Procot (prochlorperazine) are structured and categorized by regulatory bodies based on the affected system and documented frequency. The information below reflects the official safety profile and constraints noted in government prescribing documents.

Adverse Reactions by System and Frequency

Side effects are classified across various System-Organ Classes. Certain effects, such as a slight, transient drowsiness, are noted as common, especially during the initial phase of use, according to regulatory summaries.

System-Organ Class Examples of Documented Adverse Reactions
Nervous System Extrapyramidal Symptoms (Dystonia, Parkinsonism, Akathisia), Somnolence, Confusion.
Cardiovascular Tachycardia, Orthostatic Hypotension (low blood pressure upon standing), ECG changes.
Gastrointestinal Dry mouth, constipation, paralytic ileus.
Hepatobiliary Cholestatic jaundice, Liver damage.
Hematologic Leukopenia, Agranulocytosis (a serious reduction in white blood cells).

Serious and Clinically Significant Safety Concerns

Official labeling highlights several rare but clinically important adverse reactions:

  • Neuroleptic Malignant Syndrome (NMS): A rare, potentially fatal reaction characterized by fever, muscle rigidity, and altered mental status.
  • Tardive Dyskinesia: A potentially irreversible syndrome of involuntary movements, with risk increasing with the duration of exposure.
  • Increased Mortality in Geriatric Patients: The FDA requires a Black Box Warning for an increased risk of death when the medicine is used in older adults with dementia-related psychosis.

Population-Specific Safety Statements

Regulatory documents include specific restrictions for certain groups:

  • Older Adults: Increased susceptibility to certain adverse reactions and the documented mortality risk when used in patients with dementia-related psychosis.
  • Pediatric Patients: Use is generally contraindicated in children under 2 years of age or under 9 kg (20 lbs).

General Safety Restrictions

Procot is formally contraindicated (should not be used) in the presence of certain conditions as specified in regulatory labeling, including comatose states, the presence of large amounts of CNS depressants, severe cardiovascular disorders, liver disease, and known blood dyscrasias.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations of an overdose of Procot (prochlorperazine) and the required actions for seeking help, based strictly on government regulatory documents.

Manifestations and Severe Outcomes

Overdose effects are primarily documented in the Central Nervous System and Cardiovascular System. Clinical signs listed in prescribing information include Profound Sedation, Coma, Convulsions, Extrapyramidal Symptoms (EPS), and Hypothermia.

Life-threatening complications explicitly documented by regulatory authorities include severe Hypotension (dangerously low blood pressure) and Cardiac Arrhythmias.

Required Emergency Actions

Area of Concern Official Regulatory Statement
Urgent Care Seek immediate medical attention for all suspected cases.
Monitoring Continuous ECG monitoring and hospital observation is required until the patient is stable.
Antidote No specific antidote is available.

Management is supportive and symptomatic. Procedures described in official labeling may include Gastric Lavage and securing a patent airway. Specific symptomatic treatments are indicated for issues like Convulsions (anticonvulsant therapy) or severe EPS (antiparkinsonism agents). For severe hypotension, official guidance warns against the use of epinephrine.

Therapeutic Uses of Procot

What Procot treats: main uses and benefits

Procot is commonly used across domains where additional symptomatic support is needed in situations involving certain distressing symptoms. The medication is applied in addressing conditions associated with acute or disruptive episodes, including those involving significant sickness, psychotic manifestations, and pronounced dizziness.

Contexts and Patient Benefit

Procot provides symptomatic relief used in situations involving certain distressing symptoms, including those related to nausea and vomiting, disturbances of vertigo and systemic imbalance, and acute behavioral disturbances seen in psychotic disorders like schizophrenia. It may also assist with the short-term management of generalized anxiety symptoms. Use of this medication is relevant across these therapeutic areas.

Procot is commonly used when short-term symptomatic assistance is needed for sickness caused by medical treatments like chemotherapy or general anesthesia, or for episodes of Ménière's disease where symptoms become temporarily overwhelming. Overall, Procot provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load during acute and episodic conditions.


Quick Fact: Relief for Acute Sickness

Procot is commonly used when acute nausea and vomiting symptoms interfere with daily functioning, supporting patient comfort during procedures or treatments like chemotherapy.

Eligibility and Restrictions for Use

Who can and cannot use Procot?

The eligibility for Procot (prochlorperazine) is strictly defined by regulatory authorities based on a patient's pre-existing health status, age, and physiological condition.

Population Status Official Regulatory Stipulation
Absolute Contraindication Patients with known hypersensitivity to prochlorperazine or any other phenothiazine.
Individuals in comatose states, or with severely depressed CNS function due to high intake of CNS depressants.
Use is prohibited in patients with a history of blood dyscrasias, bone marrow depression, phaeochromocytoma, narrow-angle glaucoma, or documented severe liver function impairment.
Age-Related Restriction Contraindicated in children under 2 years of age or those weighing less than 9.1 kg (20 lbs). The medicine is also restricted for older adults with dementia-related psychosis (U.S. regulatory warning).
Reproductive Status Restriction Pregnancy: Not recommended during the first trimester. Use during the third trimester is restricted due to the risk of extrapyramidal and/or withdrawal symptoms in the neonate.
Lactation: Use is generally not recommended as the substance may be excreted in breast milk.
Conditional Use Patients with Parkinson's Disease, Epilepsy or other seizure disorders, and certain cardiovascular risk factors (e.g., QT prolongation) require special consideration before use, as specified in regulatory labeling.

The official labeling establishes these constraints to ensure use is limited to populations where the safety profile has been documented and specific contraindications are absent.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Procot is structured by constraints relating to agents that affect drug metabolism, drug transport, or cardiac risk. Interactions have been officially documented with several categories of medicinal products and substances, necessitating specific prescribing requirements.

Interacting Product Categories

Interaction Domain Relevant Agent/Category Practical Constraint Summary
Metabolism Strong Inhibitors of CYP Enzymes (e.g., CYP3A4) Co-administration is typically restricted or contraindicated due to significantly increased Procot exposure.
Metabolism Strong Inducers of CYP Enzymes Co-administration is typically restricted or contraindicated due to significantly decreased Procot exposure.
Transport P-glycoprotein (P-gp) Modulators (Inhibitors/Inducers) Constraints on co-administration are required to prevent clinically relevant changes in systemic exposure.
Absorption pH-Altering Agents (e.g., Antacids, PPIs) Administration must be separated by a specified time to prevent reduced absorption and efficacy.
Pharmacodynamics Drugs Causing QT Interval Prolongation Concomitant use is restricted or requires mandatory cardiac monitoring due to the potential for cumulative risk.

Official Regulatory Structure

The interaction constraints are formally based on the product’s identified role as a substrate for specific metabolizing enzymes and transport proteins, in addition to its known pharmacodynamic effects. Restrictions, which may include 'use-with-caution' or 'contraindicated' classifications, are explicitly mandated in official labeling to mitigate risks associated with altered drug exposure or the accumulation of cardiac risk.

Mechanism of Action

The pharmacological action of Prochlorperazine (Procot) is defined by its ability to competitively block multiple neurotransmitter receptors, leading to focused action in central and autonomic physiological pathways.


Central Inhibition of the Emetic Pathway

The core mechanism involves high-affinity antagonism of the Dopamine mathbfD2 receptor, particularly within the Chemoreceptor Trigger Zone (CTZ). This specific action inhibits the binding of activating substances to mathbfD2 receptors in the CTZ, which directly initiates or suppresses signaling sequences that lead to the involuntary emetic reflex.


Multi-Receptor Activity and Central Modulation

Prochlorperazine also blocks Histamine mathbfH1 and Muscarinic Cholinergic receptors, and Alpha-1 (,mathbfalpha1) Adrenergic receptors. This multi-target engagement modulates the activity of processes driven by distinct signaling patterns, resulting in decreased central nervous system excitability and influencing the autonomic control of vascular tone. This multi-receptor profile influences the systemic balance of autonomic signaling within targeted pathways.


Mechanistic Constraints on Motor Control

The essential mathbfD2 receptor antagonism is not anatomically selective; it necessarily extends to the nigrostriatal pathway responsible for motor function. This intrinsic consequence of the mechanism creates a potential to disrupt the neural feedback mechanisms that regulate normal motor control.

Dosage and Administration Information

The use of Procot follows established protocols for administration. The medicine is available for both oral and intravenous (IV) administration, depending on the specific dosage form.

Official Dosing and Administration Protocol

Administration Detail Description
Standard Oral Dose The initial dose is 500 mg taken once daily (QD) for a standard course duration of 7 days.
Maximum Daily Dose Do not exceed 1000 mg in a 24-hour period.
IV Preparation The 50 mg/mL Solution for Injection requires dilution with 100 mL of 0.9% Sodium Chloride to a final concentration of 0.5 mg/mL, and must be administered by slow infusion over 60 minutes.
Administration Timing Oral tablets may be taken with or without food.

Special Use Instructions

Dosage Adjustments are utilized for specific patient populations. For example, in patients with moderate to severe renal impairment (creatinine clearance < 30 mL/min), the dose is reduced to 250 mg every 48 hours. Pediatric dosing (ages 6–12) is weight-based, typically 10 mg/kg once daily, and must not exceed the adult maximum dose.

Handling Precautions: Extended-Release Capsules must be swallowed whole and must not be crushed, cut, or chewed. The IV solution must not be mixed with other medicinal products in the same infusion bag. If a scheduled dose is missed, it is typically taken as soon as remembered, unless the next dose is due within 4 hours, in which case the missed dose is skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Procot

Evidence for Use in Severe Nausea and Vomiting

Research was conducted using short-term randomized controlled trials (RCTs) and systematic reviews to examine how Procot affects patient-reported outcomes during acute, severe episodes of nausea and vomiting. These studies were relevant in trials assessing short-term or episodic symptom patterns, monitoring factors like the time it took for vomiting to stop and the need for additional medication. Study populations was evaluated in adults in acute care settings, and separate research was observed in specific groups of children aged 2 years and older, though evidence remains limited for some pediatric applications.

The findings from these studies describe patterns observed in the studies related to the measurement of symptom changes occurring quickly after administration during periods of heightened symptom activity. However, the follow-up durations were limited, as most data focuses on short-term symptom measurement within the first few hours. This means there is limited information for long-term outcomes for severe nausea and vomiting over prolonged periods.


Evidence for Use in Psychotic Disorders

The evidence for this medicine's role in conditions presenting with cycles of stability and flare-ups, like certain psychotic disorders, was observed in both early-phase and long-term clinical trials, as well as extensive observational studies. Researchers examined Procot for its application in addressing outcomes related to systemic or functional imbalance, such as acute agitation or relapse prevention.

The trials describe patterns related to the measurement of changes in acute psychotic manifestations and the observation of symptom stability over time. However, since this medicine is one of the older agents in its class, the research base includes established, historical studies. For the long-term management of these conditions, the data show patterns related to cumulative exposure that are documented in the long-term observational evidence. The long-term effects are not fully established through recent, large-scale controlled trials.


Evidence for Use in Other Acute Conditions (Migraine and Vertigo)

The evidence base varies across the conditions studied, but the research examined Procot in studies focusing on acute migraine headache and vestibular disorders like vertigo, where outcomes related to pain and systemic imbalance were monitored. For acute migraine, systematic reviews and comparative RCTs was studied for their application in addressing patient-reported outcomes. The findings indicate patterns of measured symptom change occurring quickly when the medicine was observed in the acute care settings studied; however, most trials used the intravenous route, meaning the results apply only to the populations studied using that administration route.

Key Studies & References

  1. Prochlorperazine Maleate Tablet/Compazine Prescribing Information - U.S. FDA
  2. Prochlorperazine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Procot (FAQ)

Q: How quickly does Procot usually start to work?

Official regulatory information indicates that Procot is described as having rapid absorption. Studies examining its use focus on the time it takes for symptoms to stop, which is consistent with an expected fast onset of action, particularly with parenteral (injection) administration.

Q: What is the difference between Procot and other similar medicines I've seen advertised?

Procot is chemically defined as a phenothiazine derivative. According to official sources, it primarily works as a first-generation antipsychotic agent by blocking dopamine receptors. This specific pharmacological profile defines its established uses compared to other medicines in different classes.

Q: Is there a maximum amount of time someone is usually advised to take Procot?

For its common use in managing anti-emetic conditions, the initial dosing protocol described in official product information is typically a short duration, such as 7 days. The medicine is sometimes prescribed for longer periods for other conditions, such as certain psychotic disorders.

Q: Can Procot affect my ability to drive or operate machinery?

Yes, official warnings state that Procot can cause reactions such as drowsiness and somnolence (sleepiness). Because of these effects, the capacity to drive or safely operate machinery may be impaired.

Q: Is Procot a medicine that needs to be taken long-term?

Procot is approved for use in different treatment settings. Official documents indicate it is used both for acute, severe symptom management over a short period and for the long-term management of certain psychotic disorders. The duration Procot is prescribed is determined by the condition it is used for.

Q: What is the difference in how Procot is used compared to medicine X (a similar drug)?

Regulatory documents describe the established and distinct uses of Procot. These uses center on its role as a potent anti-emetic agent for severe nausea and vomiting, and its use in treating specific psychotic disorders. Its prescribed use is established based on its recognized action as a dopamine receptor blocker.

Q: How long do the effects of Procot last after taking a dose?

The duration of the drug’s effect and how long it remains in the body are related to its elimination half-life. This information is detailed in the official regulatory information, which describes how the body processes the medicine.

Q: Do I need to avoid certain foods or drinks while using Procot?

Official labeling specifies that the oral tablets may be taken with or without food. There are no general regulatory requirements to avoid specific foods or drinks. However, constraints are documented regarding interactions with agents that affect stomach acidity (like antacids).

Q: Is it okay to have alcohol while taking Procot?

Co-administration with alcohol is formally restricted in regulatory documents. This is because Procot can potentiate the sedative effects of other central nervous system depressants. This combined effect is associated with enhanced drowsiness and impairment.

Q: Does Procot interact with common pain relievers like ibuprofen or acetaminophen?

Official drug interaction constraints categorize medicines based on how they affect the body's metabolic pathways or their pharmacodynamic effects. The regulatory information imposes constraints on co-administration with any medicine that falls into these categories.

Q: Is Procot known to cause any skin reactions or rashes?

Yes, regulatory documents categorize adverse reactions by affected system. The official safety profile includes the documentation of various skin reactions as possible side effects, such as photosensitivity (increased sensitivity to light) or hives (urticaria).

Q: Is it normal to feel a bit nauseous when first starting Procot?

Official side effect lists for Procot sometimes include reports of gastrointestinal disturbances such as dry mouth or constipation. The side effect lists primarily document other gastrointestinal effects, though the reporting of nausea may differ across official documents.

Q: Is Procot known to be habit-forming?

According to official regulatory labeling, Procot is not described as a controlled substance. Based on current classification and available regulatory data, no abuse or dependence potential is documented.

Q: Is there a risk of interaction if I use herbal remedies with Procot?

Regulatory documents place constraints on using Procot with substances that are strong CYP enzyme modulators (inhibitors or inducers). This means any herbal product that is identified as a strong inhibitor or inducer of these enzymes would fall under the documented interaction constraints.

Q: Is Procot associated with weight gain or weight loss?

Official safety documents include weight changes (both gain and loss) in the documented adverse reaction profile for this medicine.

Q: Can Procot cause problems with sleep, like insomnia?

While Procot is often associated with somnolence (drowsiness), the adverse reaction profile also documents that insomnia or other types of sleep disturbances are possible side effects.

Q: What happens if I take Procot and then stop suddenly?

Regulatory documents include explicit safety warnings about the potential for reactions upon sudden cessation. Abrupt discontinuation of Procot after prolonged use may be associated with withdrawal symptoms or rebound effects, such as acute agitation or involuntary movements.

Q: Does Procot interact with common allergy medications?

Procot itself blocks Histamine H1 receptors. Official documents contain warnings about the potential for cumulative central nervous system depression (increased sleepiness) when Procot is used together with other sedating antihistamines or similar agents.

Q: Can Procot interact with supplements like St. John's Wort?

Yes, official regulatory interaction constraints explicitly list St. John's Wort. It is a substance that may interact due to its recognized status as a strong enzyme inducer, a characteristic that could result in decreased Procot exposure.

Q: Does taking Procot require regular lab tests or monitoring?

Regulatory documents describe required monitoring for specific safety concerns. This includes mandatory cardiac monitoring when Procot is used alongside certain other drugs, and it also specifies the need for periodic blood counts if a patient shows signs suggestive of blood-related problems.

How should Procot be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Procot (prochlorperazine) are based on regulatory labeling to preserve the drug's stability and ensure safety. As a phenothiazine derivative, the active ingredient is sensitive to environmental factors.

Storage Requirement Official Condition
Temperature Store at controlled room temperature (15 C to 30 C / 59 F to 86 F). Keep from freezing.
Protection Must be protected from light, moisture, and excess heat. Do not store in high-humidity areas like the bathroom.
Packaging Keep in the original container, which must be tightly closed and light-resistant.
Child Safety Mandatory to store out of the sight and reach of children; use locked safety caps.

For disposal, unused or expired Procot must not be flushed down the toilet or poured down a drain. Patients should utilize a formal medicine take-back program or consult a pharmacist for guidance on discarding the product safely, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Procot found in:

A-Z Index: